Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017

被引：15
|
作者：
Frank I. Scott
Gary R. Lichtenstein
机构：
[1] University of Colorado Anschutz Medical Campus,Crohn’s and Colitis Center, Division of Gastroenterology and Hepatology
[2] Perelman School of Medicine,Gastroenterology Division
[3] University of Pennsylvania,undefined
来源：
Current Treatment Options in Gastroenterology | 2018年 / 16卷 / 1期
关键词：
Biosimilars; Indication extrapolation; Interchangeability; Infliximab; Adalimumab; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
D O I：
10.1007/s11938-018-0177-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：147 / 164
页数：17
相关论文
共 50 条
  • [31] Supporting patients with inflammatory bowel disease
    Dalibon, Pierre
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (545): : 35 - +
  • [32] Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease
    de Chambrun, Guillaume Pineton
    Blanc, Pierre
    Peyrin-Biroulet, Laurent
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (08) : 915 - 927
  • [33] Updates on the Use of Biosimilars for the Treatment of Inflammatory Bowel Disease
    Velayos, Fernando
    PRACTICAL GASTROENTEROLOGY, 2022, 46 (07)
  • [34] Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease
    Bhat, Shubha
    Limdi, Jimmy K.
    Cross, Raymond K.
    Farraye, Francis A.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (08) : 2513 - 2532
  • [35] Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease
    Shubha Bhat
    Jimmy K. Limdi
    Raymond K. Cross
    Francis A. Farraye
    Digestive Diseases and Sciences, 2021, 66 : 2513 - 2532
  • [36] Update on biosimilars in inflammatory bowel disease: Position and recommendations in Mexico
    Mayoral-Zavala, A.
    Esquivel-Aguilar, A.
    del Real-Calzada, C. M.
    Gutierrez-Grobe, Y.
    Ramos-Garcia, J.
    Rocha-Ramirez, J. L.
    Rojas-Illanes, M. F.
    Rubio-Martinez, B.
    Sanchez-Chavez, X.
    Yamamoto-Furusho, J. K.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2018, 83 (04): : 414 - 423
  • [37] Targeting TNF-α for the treatment of inflammatory bowel disease
    Billiet, Thomas
    Rutgeerts, Paul
    Ferrante, Marc
    Van Assche, Gert
    Vermeire, Severine
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (01) : 75 - 101
  • [38] Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review
    Massimo Radin
    Savino Sciascia
    Dario Roccatello
    Maria Jose Cuadrado
    BioDrugs, 2017, 31 : 37 - 49
  • [39] Adalimumab for the treatment of inflammatory bowel disease
    Wasan, Sharmeel K.
    Kane, Sunanda V.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 5 (06) : 679 - 684
  • [40] Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems
    Aljabri, Ahmed
    Soliman, Ghareb M.
    Ramadan, Yasmin N.
    Medhat, Mohammed A.
    Hetta, Helal F.
    CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
12345